tradingkey.logo

Renovaro Inc

RENB
1.420USD
0.000
收盘 12/22, 16:00美东报价延迟15分钟
251.90M总市值
亏损市盈率 TTM

Renovaro Inc

1.420
0.000

关于 Renovaro Inc 公司

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Renovaro Inc简介

公司代码RENB
公司名称Renovaro Inc
上市日期Nov 18, 2014
CEOWeinstein (David)
员工数量- -
证券类型Ordinary Share
年结日Nov 18
公司地址2080 Century Park East, Suite 906
城市LOS ANGELES
上市交易所NASDAQ Capital Market Consolidated
国家United States of America
邮编90067
电话14539179840
网址
公司代码RENB
上市日期Nov 18, 2014
CEOWeinstein (David)

Renovaro Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--

收入明细

由于公司未披露,未能获取相关数据
由于公司未披露,未能获取相关数据
业务
地区
由于公司未披露,未能获取相关数据

股东统计

更新时间: 11月16日 周日
更新时间: 11月16日 周日
持股股东
股东类型
持股股东
持股股东
占比
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
BMO Nesbitt Burns Inc.
5.79%
Gumrukcu (Serhat)
5.35%
其他
57.91%
持股股东
持股股东
占比
RS Group ApS
15.10%
Lakysa Ventures, Inc
9.67%
PasecoApS
6.17%
BMO Nesbitt Burns Inc.
5.79%
Gumrukcu (Serhat)
5.35%
其他
57.91%
股东类型
持股股东
占比
Corporation
31.30%
Investment Advisor
8.84%
Individual Investor
8.20%
Hedge Fund
1.12%
Investment Advisor/Hedge Fund
0.79%
Research Firm
0.03%
其他
49.72%

机构持股

更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
144
2.83M
12.20%
+559.32K
2025Q2
156
65.41M
35.65%
+4.54M
2025Q1
161
103.48M
60.94%
+42.30M
2024Q4
155
103.71M
63.86%
+49.62M
2024Q3
149
51.49M
35.21%
-1.80M
2024Q2
151
51.88M
36.43%
+6.39M
2024Q1
154
44.98M
32.23%
+3.81M
2023Q4
151
44.01M
67.51%
+217.77K
2023Q3
146
41.12M
71.08%
+1.11M
2023Q2
147
41.48M
71.99%
+3.87M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
RS Group ApS
1.68M
7.26%
+322.24K
+23.69%
Jul 15, 2025
Lakysa Ventures, Inc
2.15M
9.27%
+2.15M
--
Jul 15, 2025
PasecoApS
2.70M
11.65%
+1.44M
+113.93%
Jul 15, 2025
BMO Nesbitt Burns Inc.
1.36M
5.86%
+1.36M
--
Jul 15, 2025
Gumrukcu (Serhat)
1.25M
5.4%
--
--
Jul 15, 2025
The Vanguard Group, Inc.
492.46K
2.12%
-73.57K
-13.00%
Jun 30, 2025
William (Anderson Wittekind)
476.63K
2.06%
--
--
Jul 15, 2025
Millennium Management LLC
214.96K
0.93%
+213.51K
+14684.25%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
256.55K
1.11%
-424.73K
-62.34%
Jun 30, 2025
Geode Capital Management, L.L.C.
101.59K
0.44%
-135.17K
-57.09%
Jun 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
iShares Russell 2000 Growth ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Global X Russell 2000 ETF
0%
Dimensional US Core Equity 1 ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
iShares Micro-Cap ETF
占比0%
Global X Russell 2000 ETF
占比0%
Dimensional US Core Equity 1 ETF
占比0%
Proshares Ultra Russell 2000
占比0%
iShares Russell 2000 ETF
占比0%
ProShares UltraPro Russell2000
占比0%
ProShares Hedge Replication ETF
占比0%
iShares Russell 2000 Value ETF
占比0%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
Sep 24, 2025
Merger
10→1
公告日期
类型
比率
Sep 24, 2025
Merger
10→1

常见问题

Renovaro Inc的前五大股东是谁?

Renovaro Inc 的前五大股东如下:
RS Group ApS持有股份:1.68M,占总股份比例:7.26%。
Lakysa Ventures, Inc持有股份:2.15M,占总股份比例:9.27%。
PasecoApS持有股份:2.70M,占总股份比例:11.65%。
BMO Nesbitt Burns Inc.持有股份:1.36M,占总股份比例:5.86%。
Gumrukcu (Serhat)持有股份:1.25M,占总股份比例:5.40%。

Renovaro Inc的前三大股东类型是什么?

Renovaro Inc 的前三大股东类型分别是:
RS Group ApS
Lakysa Ventures, Inc
PasecoApS

有多少机构持有Renovaro Inc(RENB)的股份?

截至2025Q3,共有144家机构持有Renovaro Inc的股份,合计持有的股份价值约为2.83M,占公司总股份的12.20%。与2025Q2相比,机构持股有所增加,增幅为-23.45%。

哪个业务部门对Renovaro Inc的收入贡献最大?

在--,--业务部门对Renovaro Inc的收入贡献最大,创收--,占总收入的--%。
KeyAI